Johnson & Johnson: Hematologic Neoplasms trials

The registry lists 13 Hematologic Neoplasms studies with Johnson & Johnson as lead sponsor. 2 are open to participants now and 2 have results posted.

Phase 1 6Phase 2 4Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of JNJ-95804306 for Relapsed or Refractory Hematological MalignanciesRecruitingNCT07572006Phase 1
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Phase 2
• A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesCompletedNCT02329847Phase 1/2Results posted
• The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised ParticipantsCompletedNCT01021683Results posted
• A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT04696809Phase 1/2
• A Study of Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04557098Phase 2
• Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03399799Phase 1
• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03145181Phase 1
• A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological MalignancyTerminatedNCT02895529Phase 4
• Study of CA-18C3 in Subjects With Advanced Hematologic MalignanciesCompletedNCT01260545Phase 1
• Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised PatientsCompletedNCT01060462
• VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the NetherlandsCompletedNCT00440765
• ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.CompletedNCT00440479